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Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder
that affects the child and adolescent population. It is characterized by impairment in atten-
tion/concentration, hyperactivity, and impulsivity, all of which can impact performance of
athletes. ADHD treatment within the athletic population is a unique challenge.The research
in this field has been relatively limited. The National Collegiate Athletic Association and
International Olympic Committee both regulate the use of psychostimulants for treatment
of ADHD due to their performance-enhancing effects. In this article, authors have dis-
cussed the screening methods, pharmacological treatment, side effects, and behavioral
approaches for the treatment of ADHD in adolescent athletes.
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INTRODUCTION
Attention-deficit hyperactivity disorder (ADHD) is a neurode-
velopmental disorder that affects about 6–7% of the child and
adolescent population (1). Reports suggest that the prevalence of
this disorder is higher in athletes at both the collegiate and profes-
sional levels. Overall, ADHD is more prevalent in boys (13.2%)
than in girls (5.6%), which may explain the above-mentioned
discrepancy (2, 3). Literature is limited on how ADHD affects
adolescents during sports-related activities. As a result, there is a
paucity of literature on the treatment and management of athletes
dealing with this disorder. Due to increasing awareness, researchers
have started looking closely at the deleterious effects of ADHD in
adolescent and adult athletes.
SEARCH STRATEGIES
For this article, we searched the following databases for the period
of January 1985, to December 2013: Medline, PsychINFO, Ovid,
PubMed, and Cochrane Library. We used the following search
terms: “ADHD,” “adolescents,” “athletes,” and “sports.” Key arti-
cles were selected on the basis of topic covered, and emphasis
was placed on articles published after 2000. Reference sections of
identified publications were also searched for relevant informa-
tion. The current article is supplemented with the authors’ clinical
knowledge, and the references list was modified on the basis of
suggestions from peer reviewers.
ATTENTION-DEFICIT HYPERACTIVITY DISORDER
Descriptions of ADHD in the literature go back to the beginning
of the twentieth century. This disorder was further conceptu-
alized and refined at the time that the Diagnostic and Statisti-
cal Manual of Mental Disorders-III (DSM-III) was introduced.
ADHD is a chronic disorder that affects multiple areas of life
including education, work, family, and social functioning. If left
untreated, ADHD can have long-lasting detrimental effects on the
individual’s development and psychosocial functioning.
SIGNS AND SYMPTOMS
The Diagnostic and Statistical Manual of Mental Disorders-IV-
TR identifies inattention, hyperactivity, and impulsivity as the
three cardinal symptoms of this disorder (4). DSM-IV-TR also
requires onset of these symptoms to be before 7 years of age.
Inattentive symptoms include paying poor attention to detail,
difficulty sustaining attention, poor follow-through on instruc-
tions, poor organization, avoiding homework, losing things, being
distractible, and being forgetful. Hyperactivity symptoms include
difficulty sitting still, inappropriately leaving one’s seat, fidgeting,
running, climbing, being unusually active, and talking excessively.
Impulsive behaviors usually present as an individual’s inability to
wait for his turn in activities or blurting out answers before being
called on in class. Children with a predominance of hyperactive
and impulsive behaviors tend to present to clinical care earlier
than the ones dealing primarily with inattention (5). Literature
has also shown that a significant majority of children continue
to deal with this disorder in their late adolescent years and that
they do not “outgrow” ADHD (6). This disorder also is associated
with significant comorbidity, including mood, anxiety, and oppo-
sitional disorders, which further complicates the presentation and
treatment (7).
The Diagnostic and Statistical Manual of Mental Disorders-5
continues to include the inattention group criteria as well as the
hyperactivity and impulsivity criteria. According to the DSM-5,
ADHD symptoms must be present prior to the age of 12 years, in
contrast to the age of 7 years as required in the DSM-IV. DSM-
5 does not exclude children with autism spectrum disorder (8).
ADHD symptoms must not occur during the course of other
mental disorders such as schizophrenia, bipolar disorder, anxi-
ety disorder, dissociative identity disorder, personality disorder,
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and substance intoxication or withdrawal. Such changes to the
DSM-5 ensure that children with ADHD continue to receive care
throughout their lives as needed.
DIAGNOSIS OF ADHD
In the majority of cases, a thorough clinical interview is sufficient
to clearly establish this diagnosis. DSM-5 requires certain criteria
to be met before the diagnosis is finalized, including onset of the
symptoms before 12 years of age, presence of symptoms in more
than one setting, and psychosocial dysfunction (8).
Certain tests can be reviewed to further clarify the diagnosis,
including the Continuous Performance Test as well as the Connors
and the Vanderbilt parent and teacher rating scales. It is important
to remember that none of these tests are diagnostic, but they can be
used as supporting evidence, especially when the clinical history
is equivocal and insufficient by itself to make the diagnosis. On
occasion, thorough neuropsychological testing is also warranted.
A complete physical examination and laboratory testing are nec-
essary to rule out any medical problems that may be mimicking
ADHD symptoms (9).
PSYCHOSOCIAL DEVELOPMENT OF ADHD ADOLESCENTS
The adolescent years are marked by rapid psychosocial develop-
ment with an emphasis on successfully forming an individual
identity. During this stage, adolescents face numerous challenges
and tend to focus mostly on themselves and their present circum-
stances. They struggle to improve their self-esteem, which is largely
dependent upon their physical attractiveness to others and the role
they play in their peer group (10). Adolescents who are successful
in this stage grow to be confident and self-assured and go on to
find a role in life in which they feel comfortable. Friends and peers
tend to play a significant role during this phase of life, and learning
to be a part of the team is an important developmental task (11).
Some children with ADHD struggle with these challenges of
normal development. Their abilities to deal with the world are
somewhat limited in comparison to their non-ADHD peers (12).
They grow up having to deal with inattention, disorganization,
and limited ability to follow through on instructions. These defi-
ciencies are more pronounced if the ADHD remains undiagnosed
and, as a result, untreated. Children with ADHD tend to get more
negative feedback from their parents and teachers (13, 14). This
in turn affects their self-esteem and negatively impacts their drive
to achieve certain goals in life (15). They often feel criticized, yet
know that they have limited control over their symptoms (16, 17).
Research also has suggested that children with ADHD who feel less
able to control their behaviors tend to experience more persistence
of these behaviors (18–20).
ADHD ADOLESCENTS AND SPORTS
Participation in sports is an important part of school and college
life. This participation requires individuals to be attentive, orga-
nized, and calm and also to have the ability to wait for their turn.
These abilities are naturally lacking in children with attention-
deficit ADHD. Adolescents with ADHD also tend to struggle with
impaired motor coordination, anticipation, and planning (21).
Despite these challenges, adolescents are encouraged to par-
ticipate in sports, as it is widely accepted that this participation
improves on-task behaviors, self-confidence, and social status
within the peer group. In one study,authors examined the effects of
outdoor activities on ADHD symptoms and concluded that activi-
ties in“green”outdoor spaces appear to improve ADHD symptoms
the most (22). In another study, a regular exercise program for 5
out of 7 days over 6 weeks significantly improved ADHD-related
behaviors in young children and adolescents (23). Other authors
have found improved academic performance and overall attitude
in children with a regular schedule of physical activity (24). A
more recent study examining parental perceptions of the effects of
regular physical activity on ADHD showed a positive impact on
symptoms, with a greater benefit for symptoms of inattention and
hyperactivity compared to symptoms of impulsivity (25).
Adolescents with a hyperactivity disorder report being shy and
lonely and are unsure about themselves in a variety of different
situations. Social skills training is one of the types of therapy that
is used in the treatment of ADHD. Basic techniques in this type
of therapy include role playing, modeling, and coaching (26). As
with social skills training, participation in sports improves social
deficits and also elevates mood and motivation level (27). Ado-
lescents learn social cues and how to trust peers, adhere to rules,
and effectively participate in structured activities. This also leads
to improved relationships with peers which ultimately improves
self-esteem. Participation in sports also affects the neurochemical
signals in the brain. Regular exercise increases levels of dopamine
and norepinephrine, two vital neurotransmitters that are deficient
in individuals with ADHD (28). Elevated levels improve the ability
to stay on-task and reduce impulsive behaviors. Regular exercise
and other structured activities lead to improved communication
between neurons and further neurogenesis (29). Brain-derived
neurotrophic factor (BDNF) is the most abundant neurotrophin
in the brain (30). BDNF promotes normal brain development,
enhances learning and improves neuronal plasticity (31). Reduc-
tions in hippocampal BDNF levels are known to impair memory
and learning in laboratory animals (32). Exercise is shown to
markedly increase levels of BDNF expression in ADHD rat models
(33, 34). Exercise has shown improvements in functional, regional,
and bio-marker deficits and in hypothalamic pituitary adrenal
disruptions (35).
MANAGEMENT OF ADHD
Treatment of ADHD depends upon multiple factors, including the
extent of dysfunction in the home, school, or workplace. The age
and gender of the individual and the severity of the symptoms also
play major roles in the treatment decision-making process. Both
medication- and non-medication-related treatments are available,
with multiple studies suggesting superior results with medication
management. In reality, most adolescents with ADHD require a
combination of medication management, academic support with
individualized education or 504 plans, and behavioral therapies.
Parent training and parent-child interaction therapy are other
associated therapies that are available (36).
Stimulant medications for the treatment of ADHD
Stimulant medications are usually the first line of treatment
for ADHD and are relatively safe (37). These medications have
proven efficacy in treating the core symptoms of ADHD, including
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inattentive, hyperactive, and impulsive behaviors, and numerous
studies over the last three decades have validated the safety and
effectiveness of these medications (38–43).
Broadly, these medications can be divided into methylphenidate
and amphetamine compounds. These compounds enhance activ-
ity in both the dopaminergic and noradrenergic systems (44) and
thereby improve attention and concentration (45). By affecting
dopamine, these medications also have the tendency to increase
the heart rate and blood pressure, which is a consideration when
prescribing these medications to athletes with ADHD (46). Other
noted side effects include abdominal pain, headache, anorexia,
sleep impairment, growth problems, weight loss, jitteriness, and
constipation (47).
Stimulants medications have profound effects on individuals
with and without ADHD and as a result, can be abused in a vari-
ety of settings. In non-ADHD adolescents, stimulants improve
on-task behaviors, improve concentration, increase the ability to
learn more information in limited time, minimize fatigue, and
improve the performance level (48–50).
Table 1 is a simplified list of the available stimulant medications
and the groups to which they belong.
Other medications sometimes used to treat ADHD include
atomoxetine, guanfacine, clonidine, bupropion, and the tricyclic
antidepressants. These belong to the category of non-stimulant
drugs and can be a good alternative in case of concerning side
effects from stimulant medications (51).
Stimulant medications and effects on athletes
As mentioned above, ADHD causes numerous limitations in
the performance ability of adolescent athletes. Limited research
is available on the role and effects of stimulant medications
in this unique population, but certain reports have suggested
that the side effect profile is somewhat different in this pop-
ulation in comparison to non-athletic ADHD adolescents. In
one survey, athletes reported lack of creativity, lack of spon-
taneity, palpitations, sweating, and irritability (52). Overall, it
has been noticed that the treated ADHD adolescent athletes
have better participation and outcome in sports as compared
to their non-treated peers. Stimulants also help them achieve
the level of concentration that is necessary for adequate class
participation (53).
As stimulants improve concentration and boost performance,
some professional athletes in competitive sports consider them
beneficial and sometimes use them to gain an advantage over oth-
ers (54). There is a varied literature about the effects of stimulants
on non-ADHD athletes’ sports performance. Research has sug-
gested that these medications do not specifically improve athletic
performance but instead improve the perception that one is doing
Table 1 | Commonly used stimulant medications by drug class.
Class Brand names
Amphetamine Adderall, Adderall XR, Vyvanse
Methylphenidate Ritalin, Ritalin LA, Ritalin SR, Concerta,
Focalin, Focalin XR, Metadate CD, Methylin
Dextroamphetamine Dexedrine, Dextrostat
well (55). Other studies that have reviewed the effects of these
medications on sports have noted improved performance through
increased attention to task, improved balance, and enhanced accel-
eration (56, 57). In a study of college students, amphetamines
improved measures of acceleration, although speed and power
were not consistently increased (58). Studies have also shown that
athletes taking stimulants can exercise at higher core tempera-
tures and heart rates without a perception of increased effort or
stress (59, 60). One downside of using stimulants is therefore a
potentially increased risk of developing heat-related illness during
exercise. On the other hand, the untreated condition of ADHD
may offer certain advantages also; for example, impulsivity may
translate to spontaneity and quick decision-making.
It is because of the sense of euphoria, perception of slight
improvement in certain aspects of performance, and improved
concentration that these medications are considered to be perfor-
mance enhancing and are strictly regulated by the National Col-
legiate Athletic Association (NCAA) and International Olympic
Committee (IOC). The NCAA updated their drug testing medical
exception procedures in 2008 and now requires more stringent
documentation for ADHD diagnosed athletes. It allows for stim-
ulant use by athletes with adequate documentation of ADHD
diagnosis and evidence of continued follow up (53, 61). The drug
may be present at the time of competition.
In 1992, the IOC introduced the therapeutic use exemption
(TUE). Stimulant use by Olympic athletes for ADHD and nar-
colepsy has been approved recently under the TUE. Stringent rules
apply and approval by two independent consultants is required.
Athletes on continued stimulant use must obtain a TUE from
the World Anti-Doping Agency (WADA) prior to competing inter-
nationally (62). Athletes maintained on continued therapy must
undergo annual review. In the case of a well-documented, long-
standing diagnosis, a TUE can be granted for up to 4 years;
however, yearly reviews by an experienced clinician are still
recommended (63).
The true prevalence of ADHD in athletes is not known, as
among the athletes who have this condition, few are open about it.
Despite the risks, a few athletes have come forward and discussed
their condition openly: Michael Phelps, the multiple Olympic
gold medalist, was diagnosed with ADHD at 9 years of age; Terry
Bradshaw is a pro football Hall-of-Famer who quarterbacked the
Pittsburgh Steelers to four Super Bowl victories in the 1970s;
Pete Rose became a World Series MVP in 1975; Cammi Granato
scored more goals than any other player in the history of U.S.
women’s hockey and led her team to a gold medal at the 1998
Winter Olympics in Nagano, Japan. These are just a few examples
of the many professional athletes who have excelled despite their
disabilities related to ADHD (64).
Stimulant medications and cardiac effects
As noted above, stimulant medications have the tendency to
increase heart rate and blood pressure (65). Exercise itself has var-
ied effects on the cardiovascular system. During exercise, there is
an increased demand for oxygen by other parts of the body, includ-
ing the brain and muscles. This leads to an increased workload on
the heart and a resulting increase in heart rate to meet the demands
of the body.
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During the last few years, concerns have been raised about
the effects of stimulant medications on the cardiovascular sys-
tem. In 2005, Health Canada suspended the sale of Adderall XR
following reports of sudden deaths in children taking this medica-
tion. The U.S. Food and Drug Administration (FDA) later issued a
warning about the use of these medications in children with pre-
existing heart disease. The effects of stimulants on the heart and
their association with sudden cardiac death are still being debated,
but in 2008, the American Heart Association (AHA) published
monitoring guidelines that are currently being followed by most
physicians (66).
For varied reasons, the use of stimulant medications in athletes
has been an area of concern. It is known that ADHD diagnosed
athletes can benefit from these medications, but because of the
above-mentioned concerns, a thorough cardiac evaluation needs
to be done before the start of medications and before partici-
pation in sports (67, 68). Table 2 is a template for an adequate
cardiovascular screening before the start of stimulant medications.
Non-stimulant medications for the treatment of ADHD (69)
Atomoxetine (Strattera). Atomoxetine is a non-stimulant med-
ication that is approved by the FDA for the treatment of ADHD in
children. It can be an alternative medication in competitive sports
where stimulants are completely banned despite the clinical neces-
sity. Strattera’s side effect profile does not increase the chance of
cardiac problems. On the other hand, in 2005, the FDA issued a
boxed warning for this drug because of reports of increased sui-
cidality in individuals taking this medication (70). Atomoxetine
has also been associated with elevated serum aminotransferase
levels (>20 times of normal limit) and acute liver injury in a
Table 2 | Cardiovascular screening.
PERSONAL HISTORY
History of chest pain, palpitations, heart murmur, and hypertension
History of structural cardiac defects
History of long and short QT syndrome, right ventricular cardiomyopathy,
Brugada syndrome, and Wolff–Parkinson–White syndrome
History of cardiac surgery during infancy
Respiratory symptoms including shortness of breath
Syncope and dizziness
Kawasaki’s disease (fever lasting more than 5 days, lymphadenopathy in
neck area, redness of eyes, red lips, and red palms)
Rheumatic fever
FAMILY HISTORY
Hypertrophic cardiomyopathy
Premature cardiac death
Marfan syndrome
CARDIOVASCULAR EXAM
Heart rate, blood pressure
Palpation of redial and femoral pulses
Cardiac auscultation for systolic ejection murmur, decrescendo diastolic
murmur of aortic valve insufficiency, and holosystolic murmur of mitral
valve insufficiency
Evaluation for Marfan’s syndrome – consider EKG, slit lamp eye
examination, and echocardiography
small percentage (<0.5%) of individuals. The onset of injury was
between 3 and 12 weeks of the start of medication. Although most
cases were self-limited, a few progressed to acute hepatic failure,
requiring liver transplantation (71, 72).
Alpha-2 agonists. Clonidine and guanfacine are two other alter-
natives to stimulants for the treatment of ADHD. Clonidine is
the more sedating of the two, but both can cause this undesirable
side effect for athletes. Cardiovascular parameters including blood
pressure, heart rate, and EKG need to be evaluated before the start
of these medications (73). These medications are also available in
extended-release (ER) preparations under the brand names Intu-
niv (long-acting guanfacine) and Kapvay (long-acting clonidine)
(74, 75).
Behavioral treatment strategies for ADHD athletes
For one reason or an other, neither stimulant nor non-stimulant
medications may be the initial choice for adolescent athletes. This
is especially true for adolescents with aspirations to compete on the
national or international level. In these individuals, implementa-
tion of a dedicated behavioral program can help to improve mental
capabilities and to overcome ADHD symptoms, namely inatten-
tion and impulsivity (76). Problem focused therapies including
social skills training, self-control, the stop and think technique, and
using positive reinforcements while being consistent and main-
taining clear expectations about behaviors are some of the proven
strategies (77). The home environment plays a major role in the
expression of symptoms of ADHD (78). Homes which provide
stability, security, calmness, and structure enable children with
ADHD to perform at their best capacity (79).
Mild brain stimulation techniques and neurofeedback (NF)
improve brain wave imbalances, facilitating a calmer mental state
and therefore better communication throughout the brain (80).
NF, which uses signals from the brain’s electrical activity as feed-
back, has been studied in the last few years for treatment of
children with ADHD. In one study, NF was shown to improve
the performance of expert rifle shooters (81). Studies have shown
that over time, brain stimulation techniques can improve brain
development through neuroplasticity. NF is a valid option for
treatment, but further studies are needed to determine guidelines
for use (80, 82).
CONCLUSION
Attention-deficit hyperactivity disorder is a common disorder that
affects millions of children all over the world. These children suf-
fer from inattention, hyperactivity, impulsivity, poor self-esteem,
and academic and social problems. Because of these symptoms
and deficits in motor control, their performance in sports is also
impaired (83). Stimulant medications have an extensive litera-
ture supporting their safety and effectiveness in the treatment
of ADHD. By improving the core symptoms, these medications
improve the overall functioning of ADHD adolescents. Recently
raised concerns about cardiac problems are debatable (84, 85),
but a thorough evaluation by the physician is usually an adequate
safeguard against any unwanted side effects. Research is equivocal
on whether these medications provide an extra benefit to pro-
level athletes. Overall, adequate treatment of ADHD improves the
adolescent’s quality of life (86).
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